Investor FAQ
Show all
- Where is Strongbridge Biopharma incorporated?
- Strongbridge Biopharma is an Irish public limited company.
- Where are Strongbridge Biopharma’s U.S. headquarters?
- The U.S. operations are based in Trevose, Pennsylvania, USA.
- When was Strongbridge Biopharma founded?
- Strongbridge Biopharma was established in 1996.
- When did Strongbridge Biopharma go public in the U.S.?
- Strongbridge Biopharma priced its initial public offering on NASDAQ Global Market on October 16, 2015 and trades under the ticker symbol SBBP.
- What is Strongbridge Biopharma’s CUSIP number?
- Strongbridge Biopharma’s CUSIP number is G85347 105.
- Who is Strongbridge Biopharma’s transfer agent?
- Communication regarding transfer requirements, lost certificates, changes of address, etc., should be directed to: Computershare
Written Inquiries:
Computershare
PO Box 43001
Providence RI 02940-30001
Or by overnight delivery:
Computershare
250 Royall St.
Canton, MA 02021
Email Inquiries:
[email protected]
Telephone Inquiries:
Toll-Free: 866-490-6058 (US, Canada, Puerto Rico)
781-575-2784 (non-US)
Online Inquiries:
https://www-us.computershare.com/investor/Contact - When is Strongbridge Biopharma’s fiscal year end?
- Strongbridge Biopharma’s fiscal year end is December 31.
- How can I obtain Strongbridge Biopharma’s investor relations materials?
- You may sign up to receive Strongbridge Biopharma’s press releases and SEC filings at the following link: Email Alerts.
- How can I view the documents that Strongbridge Biopharma has filed with the U.S. Securities and Exchange Commission?
- Strongbridge Biopharma’s U.S. Securities and Exchange Commission filings can be viewed on the SEC page.
- Do you have another question that has not been answered?
- For investor relations inquiries, you may submit inquiries via [email protected], or by contacting Marcy Nanus at The Trout Group, LLC. at +1-646-378-2927 or [email protected].
For corporate or media relations inquiries, you may submit inquiries via [email protected], or by contacting Lindsay Rocco at Elixir Health Public Relations at +1-862-596-1304 or [email protected].